Saturday, May 04, 2024
NICO Corporation has unveiled its latest groundbreaking innovation, hailed as a pivotal advancement by neurosurgeons familiar with the newly introduced NICO Myriad SPECTRA System. This handheld technology is designed to revolutionize the surgical removal of grade III and IV glioma brain tumors by delivering blue excitation light, thereby enhancing tissue fluorescence.
Early adopters of the NICO Myriad SPECTRA System, praise its ability to illuminate and provide superior fluorescence to deep-seated tumors through narrow corridors.
Emphasizes how navigating deep into the brain is traditionally challenging but has been significantly facilitated by the enhanced fluorescence provided by the SPECTRA System, promising to transform surgical outcomes and positively impact patients' lives.
The key feature of the SPECTRA System is its integration of blue and white light directly onto NICO's resection handpiece, allowing precise illumination closer to the surgical site.
Neurosurgeons the flexibility to adjust intensity levels for white and blue light independently, with seamless toggling between the two without diverting attention from the surgical field.
This technological leap is poised to revolutionize fluorescence-guided surgery for high-grade glioma brain tumors, enhancing visualization and aiding surgeons in achieving maximal safe resection.
At the heart of the SPECTRA System is its ability to illuminate, resect, collect, and preserve biological tissue during the surgical removal of brain tumors and intracerebral hemorrhages, utilizing both minimally invasive and open craniotomy approaches.
This groundbreaking technology is being showcased at the American Association of Neurosurgical Surgeons (AANS) Annual Scientific Meeting, promising attendees firsthand experience of its transformative potential.
High-grade gliomas represent a significant medical challenge, with thousands of diagnoses annually in the United States alone. The SPECTRA System addresses common challenges encountered during fluorescence-guided procedures, including shadowing from instruments, microscope settings, and patient positioning, thereby offering a renewed hope for improved surgical outcomes.
Highlights the substantial evidence supporting the efficacy of fluorescence-guided surgery in improving resection outcomes and patient prognosis, positioning the SPECTRA System as a significant milestone in neurosurgical innovation.
Source: prnewswire.com
